Authors

Amit Jain, MD

Latest:

Dr. Jain on the Benefit of CDK7 Inhibitors in HR+ Breast Cancers

Amit Jain, MD, discusses the benefit of CDK7 inhibitors in hormone receptor–positive breast cancers.

Elizabeth Budde, MD, PhD

Latest:

Practice Patterns and Real Use of Epcoritamab and Glofitamab

A panel of experts discuss the role of odronextamab.

Malinda West, MD

Latest:

Dr West on Adjuvant Endocrine Therapy Plus a CDK4/6 Inhibitor in Early-Stage Breast Cancer

Malinda West, MD, MS, discusses the use of adjuvant endocrine therapy in combination with CDK4/6 inhibitors in the treatment of patients with early-stage HER2-negative breast cancer.

Vinod Ravi, MD, MS, MBA

Latest:

Final Analysis from AMPECT, an Open-Label Phase 2 Registration Trial of nab-SIROLIMUS for Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)

Dr Vinod Ravi talks about nab-SIROLIMUS and reviews the data from the AMPECT trial.

Rushil V. Patel, MD

Latest:

Developing Culturally Concordant Palliative Care for Hindu Patients and Families

Sometimes, clinicians do not acknowledge how patients' values and beliefs influence how they ascribe meaning to their illness, how they prefer to receive information, and how they make decisions until the end-of-life stage, leading to misunderstandings between clinicians and patients.

Jakub Svoboda, MD

Latest:

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Charles Ryan, MD, University of Minnesota

Latest:

ASCO 2020: Updates in Prostate Cancer Treatment

Rina Lokaj

Latest:

Adjuvant Nivolumab Does Not Provide DFS Advantage in Localized, High-Risk RCC

Adjuvant nivolumab monotherapy did not yield a disease-free survival benefit vs placebo in patients with localized renal cell carcinoma.

Todd Cooper, DO; Section Chief of Oncology, Seattle Children’s

Latest:

Breaking New Ground in Childhood Cancer

Accelerating progress in childhood cancer faces three main obstacles: funding, drugs, and family support.

Syed Nabeel Zafar, MD, MPH

Latest:

Exploring the Nuances of Postoperative Considerations in Pancreatic Cancer

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Narjust Florez, MD

Latest:

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

John Koreth, MBBS, DPhil

Latest:

Dr. Koreth on Key Objectives of the EQUATOR Trial in aGVHD

John Koreth, MBBS, DPhil, discusses the key objectives of the phase 3 EQUATOR trial in acute graft-versus-host disease.

Heather Han, MD

Latest:

Dr Han on the Investigation of Neoadjuvant Therapy Plus a Dendritic Cell Vaccine in HER2+ Breast Cancer

Heather Han, MD, discusses initial safety and efficacy results from the phase 2 NATASHA trial in patients with early-stage HER2-positive breast cancer.

Jian Zhang, MD

Latest:

Dr Zhang on the Efficacy of SIM0270 Plus Everolimus in ER+/HER2− Advanced Breast Cancer

Jian Zhang, MD, discusses SIM0270, a brain-penetrant oral SERD, in combination with everolimus, in ER-positive, HER2-negative advanced breast cancer.

Ruihua Xu, MD, PhD

Latest:

Dr Xu on the Preliminary Efficacy of SHR-A1904 in Gastric/GEJ Cancer

Ruihua Xu, MD, PhD, discusses data from a phase 1 trial investigating the CLDN18.2-targeted antibody-drug conjugate SHR-A1904 in gastric/GEJ cancer.

Wasif Saif, MD

Latest:

Dr. Saif on Recommendations for Germline Testing in Pancreatic Cancer

Wasif M. Saif, MD, MBBS, discusses recommendations for germline testing in patients with pancreatic cancer.

Marc Shapiro, MD

Latest:

Clinical Updates for the Management of Lung Cancer Brain Metastases

As improved cancer therapies are helping patients live longer, the safe and effective management of lung cancer brain metastases is coming to the fore.

Maximilian Stahl, MD

Latest:

Dr Stahl on Key Genetic Tests for Menin Inhibitor Use in AML

Maximilian Stahl, MD, discusses considerations for genetic testing to determine if patients with acute myeloid leukemia may be candidates for a menin inhibitor.

Kaci Treasure

Latest:

Personalization Is Key to Successful Mentorship

Linda Hasunuma, PhD, highlights the importance of empathy and support as it relates to mentorship, as well as advice for establishing a successful fellowship program and communication strategies.

Harrison Widelitz

Latest:

Talquetamab-Based Triplet Elicits Deep Responses in R/R Myeloma

Talquetamab plus daratumumab yields improved patient outcomes in patients with relapsed/refractory multiple myeloma.